Clinical Trials Directory

Trials / Completed

CompletedNCT02744560

Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
6 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Thalassemics can develop liver fibrosis because of iron overload and hepatitis C infection. The latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics. Excess liver iron is clearly recognized as a co factor for the development of advanced fibrosis in patients with hepatitis virus C infection. Magnetic resonance imaging represents the most available noninvasive technique to assess the level of iron in the liver.there is evidence that suggests Spirulina may help to protect against liver damage, cirrhosis and liver failure in those with chronic liver disease.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTspirulinaSpirulina in a dose of 250 mg/kg/day will be given orally for 3 months.

Timeline

Start date
2015-03-01
Primary completion
2017-12-01
Completion
2017-12-01
First posted
2016-04-20
Last updated
2018-09-11

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT02744560. Inclusion in this directory is not an endorsement.